Skip to content

Miebo Prescription Drops for Dry Eyes -FDA Approved

  • 2 min read

What is new about Meibo

Miebo is a prescription eye drop used to treat the signs and symptoms of dry eye disease (DED) by preventing excessive tear evaporation. It contains perfluorohexyloctane, a semifluorinated alkane that works to stabilize the tear film on the surface of the eye, stopping the tears from evaporating and preventing drying of the eyes】. Miebo is the first and only FDA-approved treatment for DED that directly targets tear evaporation.

How does it work?

One of the most common causes of DED is excessive tear evaporation, which can be caused by a dysfunction of the Meibomian glands. These glands produce an oil that is an important part of the tear film, preventing tears from evaporating too quickly. When the tears evaporate too quickly, the eyes become dry and inflamed, eventually causing damage to the surface of the eye,

Meibo coats the eye and prevents the eye to lose moisture to the atmosphere.

Recommended Dosage

The recommended dosage is one drop into each eye four times daily. It’s important to remove contact lenses before using the drops and wait for at least 30 minutes before reinserting them.

The side effects please

The common side effects of Miebo include blurred vision and eye rednessIt should not be used by anyone who is allergic to perfluorohexyloctane.

Show me the Science

    Contact Us



    The FDA approval of Miebo was based on results from two 57-day, multi-center, randomized, double-masked, saline-controlled studies, GOBI and MOJAVE. These studies enrolled a total of 1,217 patients with a history of DED and clinical signs of Meibomian gland dysfunction, a major cause of development and disease progression. Patients experienced relief of symptoms as early as day 15 and through day 57 with statistically significant reduction in Visual Analog Scale (VAS) eye dryness score favoring Miebo observed in both studies.

    How do I get the drops?

    Miebo was jointly developed by Bausch + Lomb, a leading global eye health company, and Novaliq GmbH, a biopharmaceutical company focusing on ocular therapeutics. It was approved by the U.S. Food and Drug Administration (FDA) on May 18, 2023, and is expected to be commercially available in the second half of that year.

    l it is important to know that you will have to visit in the eye Doctor Who needs to document that you have dry eyes. The eyecare professional will have to give a prescription for Meibo eyedrops.

    Leave a Reply

    Your email address will not be published. Required fields are marked *